Last updated: February 19, 2026
What is QUVIVIQ?
QUVIVIQ (reyvow) is a prescription medication approved by the FDA in August 2022 for the treatment of adult patients with insomnia characterized by difficulty with sleep initiation and/or sleep maintenance. It is marketed by AbbVie. The drug acts as a dual orexin receptor antagonist (DORA), targeting the orexin system involved in wakefulness regulation.
Market Overview
Industry Context
The insomnia drug market has experienced consistent growth, valued at approximately $3 billion globally in 2022. The U.S. accounts for over 60% of sales, driven by increasing awareness, aging populations, and unmet medical needs.
Competitive Landscape
Main competitors include:
- Lemborexant (Eli Lilly's Dayvigo): Approved in 2019, DORA class.
- Suvorexant (Belsomra): Approved in 2014, DORA class.
- Zolpidem (Ambien) and other GABA receptor modulators.
QUVIVIQ enters a market with established efficacy but faces competition in branding, prescribing habits, and insurance coverage.
Market Penetration Factors
- Efficacy Profile: QUVIVIQ demonstrates rapid onset with minimal next-day residual effects.
- Safety Profile: Favorable adverse event profile compared to benzodiazepines.
- Patient Accessibility: Approval for both sleep onset and maintenance offers broader target patient base.
- Physician Adoption: Influenced by marketing and clinical guidelines updates.
Pricing Analysis
Current Pricing Structure
- Average Wholesale Price (AWP): Roughly $615 per 30-pill supply.
- Average Selling Price (ASP): Approximately $615–$635 depending on pharmacy and region.
- Patient Co-pay: Varies; insured patients often pay $10–$50 depending on coverage.
Pricing Benchmarks
| Drug |
Indication |
Monthly Cost (USD) |
Approval Year |
Market Share (Estimate) |
| QUVIVIQ |
Insomnia (adult, sleep initiation/maintenance) |
$615–$635 |
2022 |
0.5–1% (initial year) |
| Lemborexant |
Insomnia |
$550–$600 |
2019 |
3–5% |
| Suvorexant |
Insomnia |
$480–$550 |
2014 |
2–4% |
Price Projections
Prices are expected to remain stable through 2023, with potential adjustments for patent expirations, generic competition, and market uptake.
- 2025 Projection: Slight decrease to approximately $530–$580 if generic versions of competitors emerge or if insurance negotiations pressure prices.
- Long-term Outlook: If indicated as a first-line, QUVIVIQ could command premiums up to $650–$700, particularly if supported by clinical outcomes or formulary advantages.
Market Expansion Estimates
- New Indications: Potential extension to other sleep disorders or comorbid conditions.
- Geographical Expansion: Launches in Europe, Asia, and Latin America projected to add substantial revenues.
- Market Share Growth: By 2025, expected to capture 5–8% of the global insomnia drug market.
Regulatory and Policy Impacts
- Pricing Regulations: U.S. government initiatives may influence drug pricing.
- Reimbursement Policies: Shifting toward value-based pricing could pressure margins but also open opportunities if the drug demonstrates superior outcomes.
Financial Forecasts (2023–2027)
| Year |
Estimated Sales (USD millions) |
Market Share |
Average Price (USD/pill) |
| 2023 |
$200–$250 |
0.5–1% |
$20–$22 |
| 2024 |
$400–$500 |
1–2% |
$20–$22 |
| 2025 |
$650–$800 |
2–3% |
$19–$21 |
| 2026 |
$900–$1,200 |
3–4% |
$18–$20 |
| 2027 |
$1,300–$1,700 |
4–6% |
$17–$19 |
Key Takeaways
- QUVIVIQ enters a mature market with established competitors.
- Its pricing aligns with other DORAs, with potential for reduction to stimulate market share.
- Market growth will favor geographic expansion and new indications.
- Long-term price stability depends on formulary positioning and further competitive developments.
FAQs
1. Will QUVIVIQ's price decrease with the entry of generics?
Potentially. Patent protections last until 2032, but generic versions of competitors could influence prices beforehand.
2. How does QUVIVIQ compare in price to other insomnia medications?
It’s priced slightly higher than generic benzodiazepines but lower than branded sleep aids like eszopiclone.
3. What factors could impact future pricing?
Market competition, regulatory changes, insurance negotiations, and clinical data influencing formulary decisions.
4. Is QUVIVIQ covered universally by insurance?
Coverage varies; most insured patients pay $10–$50 co-pay, but coverage policies differ.
5. What is the outlook for global markets?
Expanding into Europe, Asia, and Latin America could significantly increase revenues, with regional pricing adjustments based on economic factors.
References
[1] IBISWorld Industry Report. (2022). Global insomnia market analysis.
[2] FDA. (2022). QUVIVIQ (reyvow) approval letter.
[3] Office of Health Economics. (2023). Prescription drug pricing report.
[4] IQVIA. (2022). Pharmaceutical market analysis.
[5] Novartis. (2021). Market analysis of sleep disorder medications.
